Form 4: Pulmonx Director Georgia Melenikiotou Receives Significant RSU Grant

Pulmonx Corporation Director, Georgia Melenikiotou, was granted 37,153 Restricted Stock Units (RSUs) on June 2, 2025, increasing her beneficial ownership to 99,714 shares.

Summary

• Georgia Melenikiotou, a Director of Pulmonx Corporation (LUNG), acquired 37,153 shares of common stock through a Restricted Stock Unit (RSU) grant.
• The transaction occurred on June 2, 2025, with an acquisition price of $0 per share, indicating a grant rather than a purchase.
• Following this grant, Ms. Melenikiotou's total beneficial ownership of Pulmonx common stock increased to 99,714 shares.
• The RSU grant vests on the earlier of the one-year anniversary of the grant date (June 2, 2026, or the next business day) or the date of the Annual Meeting of Stockholders for the year subsequent to the grant date.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a Form 4 primarily reports a transaction, the grant of RSUs to a director is a standard compensation practice that aligns management interests with shareholders, which is generally viewed favorably.

Positives

• The grant of Restricted Stock Units to a director aligns their interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• Increasing a director's equity stake can signal confidence in the company's future prospects.

Future Outlook

The RSU grant is structured to vest on the earlier of the one-year anniversary of the grant date (June 2, 2025) or the date of the Annual Meeting of Stockholders for the year subsequent to the grant date, indicating a future equity inflow for the director contingent on continued service.

Industry Context

The granting of Restricted Stock Units (RSUs) to directors is a common practice in the medical device and broader technology sectors, serving as a key component of non-employee director compensation to attract and retain talent while aligning their long-term interests with shareholder value creation.

Comparison to Industry Standards

• The use of RSU grants as a form of director compensation is a standard practice across publicly traded companies, including those in the medical technology sector like Intuitive Surgical (ISRG), Medtronic (MDT), and Boston Scientific (BSX).
• The vesting schedule, typically over one year or tied to the next annual meeting, is also consistent with common corporate governance practices for director equity awards, aiming to foster long-term commitment and performance alignment.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the long-term performance of the company, potentially leading to more shareholder-centric decision-making.
• Employees: No direct impact mentioned, but executive compensation practices can indirectly influence overall company culture and compensation philosophy.

Next Steps

• The granted Restricted Stock Units will vest on the earlier of June 2, 2026 (one-year anniversary of grant) or the date of the Annual Meeting of Stockholders for the year subsequent to the grant date.

Key Dates

Keywords

Pulmonx, LUNG, Form 4, Restricted Stock Units, RSU Grant, Director Compensation, Insider Transaction, Equity Grant, Beneficial Ownership